(4-氯-联苯-3-基)-乙酸 | 75852-50-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氯-联苯-3-基)-乙酸
• 英文名称: 2-(4'-chloro-[1,1'-biphenyl]-3-yl)acetic acid
• 英文别名: 3-(4-chlorophenyl)phenylacetic acid；3-Biphenylacetic acid, 4'-chloro-；2-[3-(4-chlorophenyl)phenyl]acetic acid
• CAS: 75852-50-5
• 化学式: C₁₄H₁₁ClO₂
• 分子量: 246.693
• InChiKey: CEPDBVZDEVXUID-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C(Solv: hexane (110-54-3); benzene (71-43-2))
• 沸点：
  410.0±25.0 °C(Predicted)
• 密度：
  1.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-氯-联苯-3-基)-乙酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 苯 为溶剂， 反应 1.0h， 生成 3-(4-chlorophenyl)phenylacetic acid chloride
  参考文献：
  名称：

  Bisphosphonate Inhibition of the Exopolyphosphatase Activity of the Trypanosoma brucei Soluble Vacuolar Pyrophosphatase

  摘要：

  Trypanosoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar pyrophosphatase, TbVSP1, not present in humans, which is essential for the growth of bloodstream forms in their mammalian host. Here, we report the inhibition of a recombinant TbVSP1 expressed in Escherichia coli by a panel of 81 bisphosphonates. The IC50 values were found to vary from similar to 2 to 850 mu M. We then used 3D QSAR (comparative molecular field and comparative molecular similarity index; CoMFA and CoMSIA) methods to analyze the enzyme inhibition results. The R-2 values for the experimental versus the QSAR-predicted activities were 0.78 or 0.61 for CoMFA and 0.79 or 0.68 for CoMSIA, for two different alignments. The root-mean-square (rms) pIC(50) error for the best CoMFA model was 0.41 for five test sets of five activity predictions, which translates to a factor of similar to 2.6 error in IC50 prediction. For CoMSIA, the rms pIC(50) error and error factors were 0.35 and 2.2, respectively. In general, the most active compounds contained both a single aromatic ring and a hydrogen bond donor feature. Thirteen of the more potent compounds were then tested in vivo in a mouse model of T. brucei infection. The most active compound in vivo provided a 40% protection from death with no apparent side effects, suggesting that further development of such compounds may be of interest.

  DOI：

  10.1021/jm058220g
• 作为产物：
  描述：

  Methyl 4a(2)-chloro[1,1a(2)-biphenyl]-3-acetate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以86%的产率得到(4-氯-联苯-3-基)-乙酸
  参考文献：
  名称：

  非甾体抗炎药。2.具有抗炎和止痛活性的4′，5-二取代的3-联苯基乙酸及其衍生物的合成。

  摘要：

  制备了一系列5'，5-二取代的3-联苯基乙酸（5a-n）和几种α-甲基衍生物（5o-v）作为新开发的非甾体类抗炎药5'-氯-5-甲氧基-的类似物3-联苯基乙酸[1（DKA-9），R = 4-ClPh; R'= Me]，并使用角叉菜胶大鼠爪水肿和AcOH扭体试验评估抗炎和止痛活性。其中，5-氟-3-联苯基乙酸（5m）具有最高的抗炎活性，而2-（3-联苯基苯基）丙酸（5o）具有最高的止痛活性。但是，在这些测定中，它们的效力不及1（R = 4-C1Ph; R'= Me）。

  DOI：

  10.1021/jm00133a010

文献信息

• NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US20210130328A1

  公开（公告）日：2021-05-06

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及一种新型具有胸腺嘧啶骨架的化合物，这些化合物用于医药领域，特别是用于治疗癌症、HSP27相关疾病和囊性纤维化；以及含有至少一种这些化合物的药物产品。最后，提供了一种生产这些新型化合物的方法。这些化合物的一般化学式为式(I)，如权利要求书中进一步定义。
• [EN] PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4 (3H)-ONE UTILISÉS EN TANT QU'ANTAGONISTES DE TRPV4
  申请人：RAQUALIA PHARMA INC

  公开号：WO2021221169A1

  公开（公告）日：2021-11-04

  This invention relates to pyrimidin-4(3H)-one derivatives that act as modulators of the TRPV4 receptor. The present invention also relates to processes for the preparation of novel pyrimidin-4(3H)-one derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain, and urological diseases or disorders.

  这项发明涉及作为TRPV4受体调节剂的嘧啶-4(3H)-酮衍生物。本发明还涉及新型嘧啶-4(3H)-酮衍生物的制备方法，以及它们在治疗各种疾病、综合症和紊乱中的应用，特别是用于治疗炎症、疼痛和泌尿系统疾病或紊乱。
• PHARMACEUTICAL COMPOSITION AND METHOD
  申请人：Slade Rachel M.

  公开号：US20090155903A1

  公开（公告）日：2009-06-18

  The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ 42 -related diseases and disorders.

  该发明提供了化合物、制药组合物和方法，用于治疗和预防神经退行性疾病和其他与Aβ42相关的疾病和障碍。
• COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：Technische Universität Dresden

  公开号：EP3819006A1

  公开（公告）日：2021-05-12

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• Compounds with thymine skeleton for use in medicine
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US11214564B2

  公开（公告）日：2022-01-04

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。